Prostate-specific membrane antigen
According to statistics, prostate cancer is the second most common cancer in men, and in terms of malignancy, it ranks third after lung and breast cancer. Today, modern prostate cancer treatment methods have brought about huge changes. The specific membrane antigen of prostate cancer cells (PSMA) is a very specific molecular marker for the diagnosis and treatment of this disease. Today, special radioligands are used to target and bind to prostate-specific antigens, which is known as PSMA scan. The results of this method even in the advanced and spread stages of cancer bring about 80% very positive therapeutic effects. Two examples of the most widely used peptide ligands used in PSMA scanning after being labeled are PSMA-11 and PSMA-617, which are widely used in diagnostic and therapeutic processes, respectively.